Indoco cut its debt repayment plan by 22% without explanation
Management said in May it would repay ₹140 cr this year; in July it said ₹110 cr. Meanwhile, the USFDA audit remains unresolved and the rationale for the ophthalmic divestment has shifted.
What's new
- Q1 standalone revenue Rs 4,081 million, up 5.8% YoY; EBITDA margin surged to 10.3% from 3.8%.
- US revenue jumped 62.2% to Rs 459 million, but growth is gated by a pending USFDA audit.
- API revenue rose 42.4% to Rs 521 million, boosting backward integration.
- Management now targets debt repayment of ₹110 cr this year and ₹150 cr next year.
Themes from the call
Margins
EBITDA margin surged to 10.3% from 3.8% on operational efficiencies, automation, and workforce reductions, offsetting higher raw material costs.
Capital allocation
Debt repayment plan was quietly cut 22% to ₹110 cr for FY27, with no explanation; capex held to maintenance levels of ₹40-50 cr.
Regulatory
USFDA audit, described as imminent in May, remains unscheduled; new product approvals and US profitability hinge on this inspection.
Guidance watch
- FY27 EBITDA margin targeted at double digits with sequential improvement.
- Overall sales growth of 12-15% over 3 years; export business to double in 2-3 years.
- Debt repayment of ₹260 cr over 17-18 months, with ₹110 cr this year and ₹150 cr next year.
- USFDA inspection expected in next couple of months, but no firm date provided.
Risk flags
- Debt repayment target cut by 22% without explanation raises credibility questions.
- USFDA audit timeline remains vague; delayed approvals impede US growth and profitability.
- Gross margin pressure from higher starting-material costs may persist through Q3.
- Ophthalmology divestment proceeds used for debt repayment contradicts earlier strategic rationale.
Key quotes
-
"So, next financial year which is '26-'27 we have a commitment to repay 140."
— Indoco management, May 2026 -
"Our objective is to repay 110 crores this year and another 150 crores next year."
— Aditi Panandikar, Jul 2026 call
The brief
Indoco’s margin performance in Q1 was its strongest in recent quarters—EBITDA margin rose to 10.3% from 3.8% a year ago, driven by automation, workforce cuts, and better product mix. Domestic formulations held steady, US revenue surged 62% (though off a low base), and API growth of 42% reinforced the integrated model. For a company that has struggled with profitability and debt, the quarter was genuinely encouraging.
The trouble lies in what management said—and changed. In May, investors were told Indoco would repay ₹140 crore of debt this year and a similar amount annually for three years. In the July call, that commitment quietly shrank to ₹110 crore this year, a 22% reduction. No reason was offered. The inconsistency extends to the ophthalmology divestment: in May management said it was emphatically not about liquidity; in July it acknowledged the proceeds went toward debt reduction. And the USFDA audit, described as imminent two months ago, remains unscheduled, with new product approvals stuck.
The margin recovery is real. But Indoco now has a credibility gap on its financial planning and regulatory timeline. Investors can celebrate the operational turnaround—but they should also ask why the debt target moved without explanation.
Margin surprise is real, but a 22% cut in the debt plan without a reason undermines the narrative.